Intraductal papillary mucinous neoplasms (IPMN) are usually referred to as papillary mucinous tumors in the pancreatic ducts, which usually have a good prognosis after timely treatment if malignant transformation has not occurred; if malignant transformation occurs, it will be more serious. Intraductal papillary mucinous neoplasms (IPMN) account for about 1% to 3% of pancreatic tumors and 20% to 33% of pancreatic cystic tumors.IPMN have malignant potential, but most of them progress very slowly. To determine the severity of pancreatic intraductal papillary mucinous neoplasms depends on the actual condition, benign or malignant nature of the tumor, etc., and cannot be generalized. If the pancreatic intraductal papillary mucinous tumor is benign without malignant transformation, it can be clinically cured after timely surgical treatment; however, if the tumor is large, it may cause serious complications or difficulty in surgical resection. However, if the pancreatic intraductal papillary mucinous tumor has developed malignancy, it is relatively serious and requires surgical resection combined with lymph node dissection, which has a poor prognosis and a high recurrence rate. Patients with pancreatic intraductal papillary mucinous tumors need early detection, early diagnosis, early treatment and regular follow-up. In conclusion, patients with pancreatic intraductal papillary mucinous tumor should actively cooperate with standardized treatment, strengthen daily life management, and follow up on time.